(IN BRIEF) Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC)…
(IN BRIEF) Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to…
(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss…
(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly…
(IN BRIEF) Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD,…
(IN BRIEF) Sanofi has completed the acquisition of DR-0201 from Dren Bio, now renamed SAR448501, to enhance its immunology pipeline.…
(IN BRIEF) CVC Strategic Opportunities II has successfully exited its investment in Genetic S.p.A., a pharmaceutical CDMO specializing in Respiratory,…
(IN BRIEF) NIB has financed the Gene Therapy Centre in Lithuania, a groundbreaking facility advancing gene therapy research and manufacturing.…
(IN BRIEF) GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat…
(IN BRIEF) CTP has successfully developed a state-of-the-art 18,000 sqm production facility for SCHOTT Pharma at CTPark Jagodina, Serbia, where…